Tandem Investment Advisors Inc. Has $81.86 Million Stake in Johnson & Johnson (NYSE:JNJ)

Tandem Investment Advisors Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 0.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 505,100 shares of the company’s stock after selling 409 shares during the period. Johnson & Johnson comprises approximately 3.1% of Tandem Investment Advisors Inc.’s holdings, making the stock its 17th biggest holding. Tandem Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $81,856,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. China Universal Asset Management Co. Ltd. bought a new stake in shares of Johnson & Johnson during the first quarter worth $765,000. Financial Counselors Inc. boosted its position in Johnson & Johnson by 14.3% in the 1st quarter. Financial Counselors Inc. now owns 183,373 shares of the company’s stock valued at $29,008,000 after buying an additional 22,943 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Johnson & Johnson by 2.6% during the first quarter. Blume Capital Management Inc. now owns 59,265 shares of the company’s stock worth $9,375,000 after acquiring an additional 1,500 shares during the last quarter. Pegasus Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 2.6% during the first quarter. Pegasus Asset Management Inc. now owns 28,165 shares of the company’s stock valued at $4,455,000 after acquiring an additional 725 shares during the period. Finally, Smart Money Group LLC boosted its holdings in Johnson & Johnson by 31.3% in the first quarter. Smart Money Group LLC now owns 5,074 shares of the company’s stock valued at $734,000 after acquiring an additional 1,209 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $156.71 on Friday. The company has a market capitalization of $377.30 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company’s 50 day moving average price is $162.96 and its two-hundred day moving average price is $155.76.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.66 EPS. On average, analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.17%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, TD Cowen cut their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $175.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.